Hematología y Hemoterapia

Resultados: 392
Tipo Título / Nombre Autor(es) Año
Diagnosis and management of von Willebrand disease in Spain Batlle J, Pérez-Rodríguez A, Corrales I, Borràs N, Rodríguez-Trillo Á, Lourés E, et al 2018
LNHT Angioinmunoblático. A propósito de un caso Bañas H 2018
Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project Pérez-Rodríguez A, Batlle J, Corrales I, Borràs N, Rodríguez-Trillo Á, Lourés E, et al 2018
Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders Bastida JM, Lozano ML, Benito R, Janusz K, Palma-Barqueros V, Del Rey M, et al 2018
Stanniocalcin 2 Regulates Non-capacitative Ca2+ Entry and Aggregation in Mouse Platelets López E, Gómez-Gordo L, Cantonero C, Bermejo N, Pérez-Gómez J, Granados MP, et al 2018
Filamin A Modulates Store-Operated Ca2+ Entry by Regulating STIM1 (Stromal Interaction Molecule 1)-Orai1 Association in Human Platelets López JJ, Albarrán L, Jardín I, Sánchez-Collado J, Redondo PC, Bermejo N, et al 2018
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, et al 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, et al 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, et al 2018